PMCF Strategy for Successful Clinical Evidence

ื”ืืชื’ืจื™ื ืื™ืชื ืžืชืžื•ื“ื“ื•ืช ื—ื‘ืจื•ืช ืฆื™ื•ื“ ืจืคื•ืื™ ื‘ืขืช ืื™ืกื•ืฃ ื”ื ืชื•ื ื™ื ื”ืงืœื™ื ื™ื™ื ืœืื—ืจ ืงื‘ืœืช ื”ืื™ืฉื•ืจ ื”ืจื’ื•ืœื˜ื•ืจื™ (CE, FDA, AMAR)

(PhD) ื“"ืจ ื ืื™ื“ื” ื’ื•ืจืฉื•ืžื•ื‘

  • ืื™ืš ืœืคืชื— ืืกื˜ืจื˜ื’ื™ืช PMCF ื ื›ื•ื ื” ื•ืžื“ื•ื™ืงืช ืœืžื•ืฆืจ ืฉืœื™.
  • ืื™ืš ืœืชื›ื ืŸ ื•ืœื‘ืฆืข ืžื—ืงืจื™ื ืงืœื™ื ื™ื™ื ื‘ืกื‘ื™ื‘ืช postmarketing.
  • ืื™ืš ืœื”ื™ืขื–ืจ ื‘ื’ื•ืจืžื™ื ื ื•ืกืคื™ื (ืžืฉืงื™ืขื™ื, ืจื•ืคืื™ื, ืžืคื™ืฆื™ื, ืจืฉื•ื™ื•ืช) ื›ื“ื™ ืœื”ืฆืœื™ื— ื‘- postmarketing study.
  • ืื™ืš ืœื‘ื ื•ืช clinical evidence ื—ื–ืง ืœืœื ื‘ื™ืฆื•ืข ืžื—ืงืจ ืงืœื™ื ื™.

ื“”ืจ ื ืื™ื“ื” ื’ื•ืจืฉื•ืžื•ื‘ ย (PhD),ื‘ืขืœืช ื ืกื™ื•ืŸ ืฉืœ ืœืžืขืœื” ย ืž-25 ืฉื ื” ื‘ืชืขืฉื™ื™ืช ื”ืžื—ืงืจ ื”ืงืœื™ื ื™ ื‘ืชื—ื•ืžื™ ื”ืฆื™ื•ื“ ื”ืจืคื•ืื™, ืคืืจืžื”, ื‘ื™ื•ื˜ื›ื ืœื•ื’ื™ื”, ื‘ืชืขืฉื™ื” ื”ืžืงื•ืžื™ืช ื•ื”ื‘ื™ื ืœืื•ืžื™ืช.

ืžื ื”ืœืช ืคืจื•ื™ืงื˜ื™ื ืงืœื™ื ื™ื™ื ื•ืคื™ืชื•ื— ืืกื˜ืจื˜ื’ื™ื•ืช ืงืœื™ื ื™ื•ืช ืžื•ืœ ื”ืจืฉื•ื™ื•ืช ื‘ืืจื””ื‘ ื•ืื™ืจื•ืคื”.

ื”ื•ื•ื‘ื™ื ืจ ื”ื–ื” ื›ื‘ืจ ื ืขืจืš, ื›ื“ื™ ืœืงื‘ืœ ืงื™ืฉื•ืจ ืœืฆืคื™ื™ื” ื‘ื•ื•ื‘ื™ื ืจ ื”ืžื•ืงืœื˜ ืื ื “ืฆื•ืจ ืงืฉืจ” ื•ื‘ืงืฉ ื”ืงืœื˜ื” ืžืก’ 102.

This Webinar was already held, to receive a link to watch the recorded Webinar
please contact usย and ask for recording No.#102.